Scarborough Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$820K Sell
723
-10
-1% -$10.2K 0.09% 76
2026
Q1
$674K Buy
+733
New +$743K 0.07% 91
2025
Q2
Sell
-563
Closed -$465K 483
2025
Q1
$465K Buy
+563
New +$468K 0.07% 84
2024
Q4
Sell
-717
Closed -$635K 116
2024
Q3
$635K Buy
+717
New +$645K 0.1% 54
2024
Q1
Sell
-465
Closed -$271K 576
2023
Q4
$271K Buy
465
+32
+7% +$18.7K 0.06% 68
2023
Q3
$233K Buy
+433
New +$223K 0.06% 64

Other funds holding LLY

Scarborough Advisors's LLY Position: Q2 2026 in Review

Scarborough Advisors reduced its Eli Lilly (LLY) stake by 1.4% in Q2 2026, selling an estimated $10.2K and leaving 723 shares worth $820K. The position accounts for 0.09% of the portfolio, ranked #76.

Scarborough Advisors first reported a position in LLY in Q3 2023 and has held it in 6 quarters since. 4,601 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Scarborough Advisors held 723 shares of Eli Lilly worth $820K as of Q2 2026.
  • Scarborough Advisors sold 10 Eli Lilly shares in Q2 2026, an estimated $10.2K.
  • Eli Lilly made up 0.09% of Scarborough Advisors's portfolio in Q2 2026, its #76 holding.
  • Scarborough Advisors first reported a position in Eli Lilly in Q3 2023 and has held it in 6 quarters since.
  • 4,601 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Scarborough Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.